Figure 2

Baseline in vitro parameters of GC sensitivity in healthy controls, tREACH, and FLARE patients. The IL-2 assay (A) and GILZ-assay (C) were performed in both tREACH and FLARE patients (bioassays in 32 patients, GC-binding assay in 32 patients, bioassays and GC-binding assay in 27 patients; control groups for the bioassays (n = 20) and binding assay (n = 16) were not the same). As secondary outcome, IL-2 repression (B) and GILZ induction (D) was calculated as follows: $IL-2repression=100\times \frac{\mathsf{\text{(IL}}2-\mathsf{\text{expression}},\mathsf{\text{PHA)}}-\mathsf{\text{(IL2}}-\mathsf{\text{expression,}}\mathsf{\text{333nM)}}}{\left(IL2-expression,PHA\right)}$$GILZinduction=100\times \frac{\mathsf{\text{(GILZ}}-\mathsf{\text{expression, 333nM)}}}{\mathsf{\text{(GILZ}}-\mathsf{\text{expression, PHA)}}}$ The numbers of GRs (E) and the affinity of the receptor (F) were determined in FLARE patients only. EC₅₀, half maximal effective concentration. P values were calculated by using ANOVA and Bonferroni post hoc correction; normalized data were used where appropriate.